# ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma

> **NCT07505849** · PHASE2 · NOT_YET_RECRUITING · sponsor: **KeshuZhou** · enrollment: 100 (estimated)

## Conditions studied

- Follicular Lymphomas

## Interventions

- **DRUG:** Zanubrutinib+R2
- **DRUG:** R2

## Key facts

- **NCT ID:** NCT07505849
- **Lead sponsor:** KeshuZhou
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2030-03-23
- **Final completion:** 2030-03-23
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505849, "ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07505849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*